MM13429 - Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease
This new Article comprises Subregulatory Guidance for removal of NCD 220.6.20 from the Medicare National Coverage Determination (NCD) Manual, effective October 13, 2023 and that MACs will make coverage determinations for Positron Emission Tomography (PET beta amyloid imaging for dementia and neurodegenerative disease. MLN Matters (MM) Articles are based on information contained within Change Requests (CRs). In this case, this article is based on content within CR13429 that is posted on the CMS website at https://www.cms.gov/files/document/r12364CP.pdf.
Final
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: November 20, 2023
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.